✦ LIBER ✦

Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART)

✍ Scribed by R. López-Vélez; J. L. Casado; V. Pintado

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 135 KB
Volume: 7
Category: Article
ISSN: 1198-743X
DOI: 10.1046/j.1198-743x.2001.00270.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Skeletal muscle involvement in human imm

Skeletal muscle involvement in human immunodeficiency virus (HIV)–infected patients in the era of highly active antiretroviral therapy (HAART)

✍ François-Jérôme Authier; Patrick Chariot; Romain K. Gherardi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 564 KB

Soluble urokinase plasminogen activator

Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy

✍ Ove Andersen; Jesper Eugen-Olsen; Kristian Kofoed; Johan Iversen; Steen B. Hauga 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB

## Abstract Circulating soluble urokinase plasminogen activator receptor (suPAR) reflects the immune and pro‐inflammatory status of the HIV‐infected patient. Highly active antiretroviral therapy (HAART) suppresses suPAR. Independent of the immune response to HAART, suPAR remains elevated in some HI

Impact of highly active antiretroviral t

Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients

✍ Mark A. Winters; Aarthi Chary; Robert Eison; David Asmuth; Mark Holodniy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 1 views

## Abstract Many hepatitis C virus (HCV)‐infected patients are also infected with HIV, and undergo antiretroviral (ARV) treatment for their human immunodeficiency virus (HIV) infection. Due to changes in HIV burden and immunologic status, HIV ARV treatment may have indirect effects on the HCV popul

Effects of potent antiretroviral therapy

Effects of potent antiretroviral therapy on the immune activation marker soluble CD27 in patients infected with HIV-1 subtypes A–D

✍ Ann Atlas; Tran Thi Thanh Ha; Anna Lindström; Anna Nilsson; Annette Alaeus; Fran 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 1 views

## Abstract HIV‐1 genetic subtypes might have a different impact on disease progression and response to antiretroviral therapy (ART). Few data are available on the immune activation profile in patients with different HIV‐1 subtypes. We have tested by ELISA the plasma levels of an immune activation